MedTrace Logo

Phase 1 First in Human Study of ZN-d5 as a Single Agent

NCT04500587 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2024-09-19

No results posted yet for this study

Summary

Phase 1 dose escalation study of ZN-d5 in subjects with relapsed or refractory non-Hodgkin lymphoma (NHL) or acute myeloid leukemia (AML).

Conditions

Interventions

DRUG

ZN-d5

Oral agent; 25 mg or 100 mg formulation

Sponsors & Collaborators

  • K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • K-Group Alpha Inc. /a subsidiary of Zentalis Pharmaceuticals · K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-13
Primary Completion
2023-12-12
Completion
2023-12-12
FDA Drug
Yes

Countries

  • Australia
  • Bulgaria
  • Croatia
  • Poland
  • South Korea
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04500587 on ClinicalTrials.gov